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SUMMARY

Most patients diagnosed with resected pancreatic
adenocarcinoma (PDAC) survive less than 5 years,
but a minor subset survives longer. Here, we
dissect the role of the tumor microbiota and the immune system in influencing long-term survival.
Using 16S rRNA gene sequencing, we analyzed
the tumor microbiome composition in PDAC patients with short-term survival (STS) and long-term
survival (LTS). We found higher alpha-diversity in
the tumor microbiome of LTS patients and
identified an intra-tumoral microbiome signature
(Pseudoxanthomonas-Streptomyces-Saccharopolyspora-Bacillus clausii) highly predictive of long-term
survivorship in both discovery and validation cohorts. Through human-into-mice fecal microbiota
transplantation (FMT) experiments from STS, LTS,
or control donors, we were able to differentially
modulate the tumor microbiome and affect tumor
growth as well as tumor immune infiltration. Our
study demonstrates that PDAC microbiome composition, which cross-talks to the gut microbiome,

influences the host immune response and natural
history of the disease.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a disease of near
uniform mortality (Hidalgo, 2010; Kamisawa et al., 2016; Miller
et al., 2016). Most patients present with advanced stage disease
and the prognosis is dismal, with a 5-year overall survival of 9%
(Siegel et al., 2018). Even when patients can undergo surgical
resection, the recurrence rate is very high and median overall
survival varies between 24–30 months (Siegel et al., 2018).
Despite this, a minor subset of patients survives more than 5
years after surgery (Dal Molin et al., 2015; DeSantis et al.,
2014). The factors that determine such enigmatic long-term survival are unknown. It is widely accepted that the cancer genomic
landscape can be predictive of overall survival and response to
therapy (Le et al., 2015; Ock et al., 2017; Vogelstein et al.,
2013). However, analysis of stage-matched PDAC long-term
survivors has not demonstrated significant genomic differences
compared to those patients with shorter survival (Dal Molin et al.,
2015; Makohon-Moore et al., 2017). Recently, Balachandran
et al. (2017) have used an in silico prediction approach to demonstrate that PDAC tumors from long-term survivors have high
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quantity and quality of neoantigens, and stronger infiltration and
activation of CD8+ T cells. Interestingly, the neoantigens exhibited homology to infectious disease-derived peptides, suggesting a neoantigen molecular mimicry with microbial epitopes
(Balachandran et al., 2017). These data suggest that microbial
host factors, independent of the genomic composition of the tumor, may determine tumor behavior and patient outcomes.
The key role of the gut microbiota as a host factor mediating
tumor responses to chemotherapy and immunotherapy in patients with melanoma and lung cancers has been recently highlighted (Gopalakrishnan et al., 2018; Matson et al., 2018; Routy
et al., 2018). These studies suggest that gut bacteria influences
the activation of the immune system, promoting cancer-associated inflammation and ultimately affecting tumor responses to
therapies. This information has allowed the stratification of
patients into responders and non-responders using the microbiota composition as a predictive biomarker of response to
immunotherapy.
Recently, it was reported the presence of Gammaproteobacteria (GP), besides other bacteria, in human PDAC. Importantly,
they reported that GP is able to metabolize gemcitabine (20 ,20 -difluorodeoxycytidine) into its inactive form (20 ,20 -difluorodeoxyuridine), suggesting that the presence of this bacteria in PDAC may
be responsible for the tumor resistance to gemcitabine (Geller
et al., 2017). Additionally, Pushalkar et al. (2018) detected specific gut and tumor microbiome in murine models of PDAC, suggesting potential bacterial translocation from the intestinal tract
into the peritumoral milieu. Bacterial ablation with antibiotics in
a PDAC orthotopic mouse model reshapes the tumor microenvironment, inducing T cell activation, improving immune surveillance, and increasing sensitivity to immunotherapy. Together,
these data suggest that modulating the gut and/or tumor microbiome could emerge as a novel strategy to sensitize tumors to
therapeutics.
Despite all this knowledge, the composition of the human
PDAC microbiome that contributes favorably or adversely to
the natural history of pancreatic cancer remains incompletely
studied. This represents a significant unmet need, as most
chemotherapeutic and immunotherapeutic agents that have
proven efficacy in other malignancies have limited efficacy in
PDAC (Garrido-Laguna and Hidalgo, 2015; Manji et al., 2017).
To help address this, we designed a study focused on dissecting
the tumor microbiota of independent cohorts of PDAC patients
at two geographically disparate tertiary care institutions (studying long-term versus short-term survivors) to gain insights on
the host-related influences that might guide this unusual longterm survival. Furthermore, we have performed human fecal microbial transplants from patients with PDAC, survivors of PDAC,
and healthy controls to assess the capacity of the gut microbiome to shape the tumor microbiome, modulate the immune
system and, ultimately, affect tumor growth.
RESULTS
Tumor Microbial Diversity Is Associated with Better
Outcomes in Resected PDAC Patients
To explore the role of the human tumor microbiome composition
in mediating clinical outcomes of PDAC patients, we used a
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discovery cohort to compare surgically resected patients who
survived more than 5 years after surgery, or long-term survivors
(LTS) (median survival 10.1 years), to stage-matched short-term
survivors who survived less than 5 years after surgery (shortterm survival [STS]; median survival 1.6 years) from UT MD
Anderson Cancer Center (MDACC) in Houston, Texas (Figure 1A;
Table 1). Patients in LTS and STS groups were matched with
respect to age, gender, stage, and prior therapies, including antibiotics use, neoadjuvant treatments, or adjuvant treatments
(Table 1). We then used a validation cohort with similar survival
characteristics from Johns Hopkins Hospital (JHH) in Baltimore,
Maryland. Bacterial DNA was extracted from 68 surgically resected PDAC tumor (36 LTS and 32 STS), and taxonomic
profiling via 16S rRNA gene sequencing was performed. We first
measured the tumor microbial diversity using different methodologies (observed taxonomic units [OTUs], Shannon and Simpson indices) and found that alpha-diversity of the tumor microbiome, defined as the number of species present within each
tumor sample (Kurilshikov et al., 2017), was significantly higher
in the LTS patients compared with STS on both the MDACC discovery cohort (p < 0.0005, p < 0.0005, and p < 0.05 for
each alpha-diversity index) and the JHH validation cohort
(p < 0.005, p < 0.005, and p < 0.005 for each alpha-diversity indice) (Figure 1B). Based on these results, we then tested the relationship between PDAC tumor microbial diversity and overall
survival (OS) in the MDACC cohort by stratifying the patients in
two groups based on median diversity obtained by Shannon index. As expected, we found that patients with high alpha diversity had significantly prolonged overall survival (median survival:
9.66 years) than those with low alpha diversity (median survival:
1.66 years) using univariate Cox proportional hazard models
(Figure 1C). The relationship between tumoral microbial diversity
and survival actually allowed for the stratification and redistribution of PDAC patients according to alpha diversity value (high or
low) (Figure 1C). Importantly, we assessed for potential contributors to microbial diversity, including clinico-pathological features, body mass index, sex, smoking, neoadjuvant and adjuvant
therapies, as well as antibiotics use, and were not able to find any
significant association (Figure S1). Recent studies have proposed that a high microbial diversity in the gut microbiome is
associated with favorable outcomes to treatment (Gopalakrishnan et al., 2018). On the contrary, an imbalance in the gut
microbiome or dysbiosis is associated with poor responses to
these therapies and associated with chronic diseases and cancer development (Ferretti et al., 2017; Human Microbiome Project Consortium, 2012b; Kundu et al., 2017; Lloyd-Price et al.,
2017; Shoemark and Allen, 2015). Our findings indicate that
the tumor alpha diversity could serve as a predictor of survival
outcome in resected PDAC patients, suggesting the potential
relevance of the microbiome composition in mediating pancreatic cancer progression.
To extend our understanding of the role of microbiome diversity and its association with survival, we aimed to detect whether
phylogenetic relationships exist between the bacterial communities enriched in the PDAC milieu of STS and LTS. We used
beta-diversity to generate a principal coordinate analysis
(PCoA) using unweighted-UniFrac distances (Lozupone et al.,
2011) and using Bray-Curtis metric distances (McMurdie and

Figure 1. Tumor Microbial Diversity Influences
the Outcome of PDAC Patients
(A) Kaplan-Meier plot of MDACC cohort PDAC
patients.
(B) Alpha diversity boxplot (observed species,
Shannon and Simpson reciprocal) in MDACC and
JHH cohorts of PDAC patients.
(C) Kaplan-Meier plot of MDACC cohort PDAC
patients defined by alpha diversity.
(D) Principal coordinate analysis (PCoA) using
unweighted-UniFrad of beta diversity.
(E) PCoA using Bray-Curtis metric distances of beta
diversity.
See also Figure S1.

Holmes, 2013). A clear clustering between OTUs from LTS and
STS was revealed by both methods in both independent cohorts
(Figures 1D and 1E), suggesting that the tumor microbial communities exhibit phylogenetic closeness within each group
(p < 0.05).
Tumor Microbiome Communities Are Significantly
Different between LTS and STS
Considering the relationship between PDAC intra-tumoral bacterial diversity and overall survival, we next sought to determine if
there were differences in the tumor microbiome composition between PDAC LTS and STS. To this end, we first assessed the
general landscape of the tumor microbiome on all patients
from both cohorts that revealed the presence of similar communities (Figure 2A). We then compared enrichment of OTUs in LTS
versus STS, which revealed enrichment for specific bacterial

communities in each group at the various
taxonomic level (Figures S2A–S2E). When
we evaluated for the influence of neoadjuvant and adjuvant therapies and antibiotics
use in MDACC cohort, we did not detect significant differences in the taxonomic composition at the order level (Figures S2F–S2H).
To further investigate these findings, we
focused on our discovery cohort and conducted high dimensional class comparisons
using linear discriminant analysis of effect
size (LEfSe) (Segata et al., 2011) that detected marked differences in the predominance of bacterial communities between
LTS and STS (Figures 2B and 2C): The
LTS tumors exhibited a predominance of
Alphaproteobacteria, Sphingobacteria, and
Flavobacteria at the class level. In contrast,
the PDAC STS cases were dominated by
Clostridia and Bacteroidea at the class level
(Figures 2B and 2C). We then interrogated
whether the tumor microbiome can be
segregated by comparison heatmap based
in the OTU abundance at the genus level using patient’s survival as a variable (Figure 2D). The genus features were selected
using logistic regression combined with
LASSO (see STAR Methods). We visualized the differential taxonomic communities’ differential segregation according to the
survival of the PDAC patients. The LTS patients showed an
enrichment on Proteobacteria (Pseudoxanthomonas) and Actinobacteria (Saccharopolyspora and Streptomyces), while no
predominant genus was detected in the STS tumors. We then
stratified patients into high versus low categories based on their
median relative abundance of these three taxa (Pseudoxanthomonas, Saccharopolyspora, and Streptomyces). Significantly
better outcomes were predicted for PDAC patients with higher
abundance of Saccharopolyspora (Hazard Ratio [HR] = 13.47,
95% confidence interval [CI] 4.672–38.83), Pseudoxanthomonas
(HR = 5.885, 95% CI 2.37–14.61), and Streptomyces (HR =
4.572, 95% CI 2.033–10.28) (Figure 2E; Table S1A). Considering
that all the above comparisons were done in the discovery
cohort, we then proceeded to validate the relative abundance
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Table 1. Clinico-pathological Characteristics of MDACC Cohort
PDAC Patients
Patients Characteristics

STS (n = 22)

LTS (n = 21)

p value

Overall survival (years)

1.62

10.14

<0.0001

Surgery date

1999–2014

2000–2010

Female

9

11

Male

13

10

Median

62.05

62.71

Range

46–74

44–73

Gender
0.45

Age (years)
0.69

Race
Caucasian

19

20

Asian

0

1

African-American

1

0

Hispanic

2

0

IB

2

1

IIA

7

10

IIB

13

10

0.48

Stage
0.56

Neoadjuvant therapy (chemo-radiation)
Yes

14

17

No

8

4

0.31

Adjuvant therapy
Yes

14

11

No

8

10

0.45

Antibiotics use (pre-surgery)
Yes

14

11

No

8

10

Yes

12

10

No

10

11

0.45

Biliary obstruction
0.64

of top 3 hits in the JHH cohort and found that Pseudoxanthomona, Saccharopolsypora, and Streptomyces were also significantly more abundant in LTS versus STS from this cohort (Figure 2F). We then used these three genera with higher
abundance in LTS to run area under curve (AUC)-receiver operator characteristic (ROC) analysis. We found that the combination of these Top 3 taxa (Pseudoxanthomonas, Saccharopolyspora, and Streptomyces) resulted in an AUC of 88.89 in the
discovery cohort and 86.67 in the validation cohort (Figure 2G).
We then attempted to assess for differences in mean relative
abundance of species between LTS and STS that could potentially
increase predictive value of long-term survivorship and found two
species significantly enriched in LTS versus STS in the discovery
cohort: Bacillus clausii (1.78% versus 0%, false discovery rate
[FDR] adjusted [adj] p value: 0.001) and Saccharopolyspora rectivirgula (1.91% versus 0.26%, FDR adj p value: 0.001) (Table S1B).
Because Bacillus clausii belongs to a genus different from the
three described, we tested its addition to the signature to predict
LTS. While the individual AUC were 88.10 and 63.3 in the discov-
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ery cohort and validation cohorts, respectively, when we added
Bacilus Clausii to the three genus signature, the AUC in the discovery cohort increased to 97.51 and in validation cohort to 99.17
(Figures 2G and 2H). These data suggest that the presence and
abundance of these three taxa communities Saccharopolyspora,
Pseudoxanthomonas, and Streptomyces, added with the presence of Bacillus Clausii, could influence and predict long-term survivorship in PDAC patients.
To definitively confirm the presence of intratumoral bacteria in
PDAC cases, we conducted several additional experiments. We
first performed rRNA fluorescence in situ hybridization (FISH) in a
subset of archival Formalin-Fixed Paraffin-Embedded (FFPE)
PDAC samples, using a specific probe that targets bacterial
16S rRNA. The FISH analysis of bacterial 16S rRNA confirmed
the presence of bacterial DNA in all PDAC samples analyzed
(Figure S3A). Additionally, in the same set of FFPE samples,
we detected the presence of bacterial lipopolysaccharide
(LPS) by immunohistochemistry using an antibacterial LPS antibody, as previously performed (Figure S3B) (Geller et al., 2017).
Consistently, this approach confirmed the presence of intratumoral bacterial in all PDAC samples evaluated (Figure S3B).
Furthermore, to verify the presence of bacteria in frozen samples, we analyzed 9 frozen PDAC tissue samples matched to
FFPE specimens that were previously analyzed. The 16S rDNA
PCR demonstrated the presence of bacterial DNA in the 9
PDAC frozen samples analyzed (Figure S3C). Additionally, we
sought the presence of Saccharopolyspora rectivirgula, one of
the top species enriched in LTS versus STS, using primers designed for this species and isolated bacteria as a positive control, and we detected positive bands on 6 out of 6 LTS PDAC
frozen samples analyzed (Figure S3D).
Additionally, to confirm whether the overall tumor bacterial
composition was similar between frozen and FFPE samples,
and to exclude the possibility that most of bacteria previously
found was an artifact of FFPE fixation, we performed 16S rRNA
gene sequencing of frozen tissue and compared it to the corresponding FFPE samples (Figure S3E). The data showed similar
taxonomic composition between FFPE and frozen PDAC samples, and notably, no statistically significant differences were
found between their taxonomic compositions of both types of
samples (Figure S3E; Table S2). Additionally, we used frozen
PDAC samples to obtain and isolate bacteria from the tissue (Figure S3F). These colonies were selected and DNA was extracted
for subsequent PCR amplification of the 16S rDNA (Figure S3G).
Overall, the results obtained from all of these approaches
confirmed the presence of bacteria in the PDAC samples
including some of the species enriched in LTS.
The Tumor Microbiome Shapes Immune Responses
Promoting T Cell Activation
The gut microbiota plays a pivotal role in shaping the immune system (Atarashi et al., 2013; Mazmanian et al., 2008; McAllister et al.,
2014). Recent studies have described that the gut microbiota
composition can improve responses to immunotherapy by modulating the immune system (Gopalakrishnan et al., 2018; Matson
et al., 2018; Riquelme et al., 2018; Routy et al., 2018; Vétizou
et al., 2015). We hypothesized that tumoral bacteria has the ability
to shape the immune tumor microenvironment that can influence

(legend on next page)
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the natural history of the cancer. We used singleplex immunohistochemistry, as well as multiplex immunofluorescence staining to
delineate the tumor immune infiltrates in the discovery cohort
(MDACC). We found greater densities of CD3+ and CD8+ T cells
in the LTS compared with the STS patients (p = 0.0273 and
p < 0.0001, respectively) (Figures 3A–3C). We also detected significantly higher number of granzyme B+ (GzmB) cells in the LTS (Figures 3A and 3B, bottom) (p = 0.04), while no significant differences
were detected in regulatory T cells (CD3+ FOXP3+), macrophages
(CD68), or MDSC (CD66b) (data not shown). Consistently, we
found greater densities of CD8+ T cells in the LTS compared
with the STS patients (p = 0.008) in the validation cohort (Figures
3D and 3E). The Spearman rank-order correlation demonstrated a
significant positive correlation between CD3+, CD8+, and GzmB+
tissue densities and the overall survival of PDAC patients (p = 0.03,
p < 0.001, and p = 0.01, respectively) (Figure 3F). Interestingly, we
found a strong significant correlation between CD8+ and GzmB+
tissue densities with microbiome diversity (Figure 3F, bottom),
suggesting that the tumor microbiome diversity may influence
both the extent of immune infiltration and the degree of activation
of CD8+ T cells. Finally, when we correlated the CD8+ T cell tissue
densities with the top-three enriched genus in LTS patients,
Saccharopolyspora, Pseudoxanthomonas, and Streptomyces,
we found a positive Spearman correlation between the two variables (p < 0.0001, p = 0.006, and p < 0.0001, respectively) (Figure 3G). These findings suggest that the tumor microbiome diversity and the presence of these three genera in the tumor may
contribute to the anti-tumor immune response by favoring recruitment and activation of CD8+ T cells.
Microbiome Communities from LTS and STS Are
Associated with Different Metabolic Pathways
It has been demonstrated that microbiota imbalances can
induce systemic metabolic alterations (Devaraj et al., 2013;
Nieuwdorp et al., 2014). Conversely, metabolic dysfunction
can also induce microbiome imbalances (Cani, 2017). Based
on this data, we next assessed if the intra-tumoral microbiome
is associated with host metabolic pathways. We used phylogenetic investigation of communities by reconstruction of unobserved states (PICRUSt) (Langille et al., 2013), a technique which
uses evolutionary modeling, to predict metagenomes from 16S
data and reference genome databases (Kanehisa and Goto,
2000). Predicted metagenomes were then used as inputs for

metabolic reconstruction, using level 2 KEGG Pathways and/or
KEGG modules between LTS and STS groups (MDACC cohort;
FDR adj p < 0.05), were mean-centered and visualized as a heatmap by linear discriminant analysis (LDA) to assess enrichment
and depletion between the two groups. PICRUSt analysis identified 26 core functional modules present across all PDAC
samples with a coverage of > 90% and p < 0.05. We detected
enrichment of differential pathways between LTS and STS
groups. Predicted functional categories involved in important
cellular functions were associated with diverse metabolic and
energetic processes (Figures S4A and S4B). The LTS cases exhibited enrichment in the pathways related to metabolism of
amino acids, xenobiotics, lipids, terpenoids, and polyketides,
besides other cellular functions. Significantly better outcomes
were predicted for PDAC patients demonstrating enrichment in
xenobiotics biodegradation and lipids metabolism pathways
(HR = 5.198, 95% CI 1.07–25.06 and HR = 4.528, 95% CI
1.54–13.305, respectively) (Figure S4C). In contrast, the STS
cases demonstrated enrichment in synthesis and processing
of proteins, processing of genetic information, energetic and
nucleotide metabolism, replication, and repair. Some of the
pathways shared by both groups, and probably not directly
related to the differential outcomes of patients, were related to
enzymes, cancer, excretory, and circulatory system. The
PICRUSt taxonomic functional relationships suggest that the
composition of the intra-tumoral microbiome determines a differential enrichment of metabolic functional pathways between
LTS and STS cases, which may influence patient survival.
Gut Microbiota Can Influence Tumor Microbiota and
Tumor Growth
We asked whether the gut microbiome can modulate the intratumoral microbiome, and to this end, we collected stools, PDAC
tumor specimens, and non-tumoral adjacent normal tissue
from 3 patients who underwent Whipple surgery. We compared
the taxonomic composition of matched samples and found that
the human gut microbiome represents 25% of the human tumor microbiome, while it is absent from the normal adjacent tissue (Figure 4A). Because the bacterial composition found in
normal adjacent tissue differs from that found in the tumor, it
suggests that the tumor microbiome might be unique. This
data suggests that the gut microbiota has the capacity to specifically colonize pancreatic tumors. To determine whether we can

Figure 2. Tumor Microbiome Communities Are Significantly Different between LTS and STS
(A) Bar plots of the class taxonomic levels in MDACC and JHH cohorts of PDAC patients. Relative abundance is plotted for each tumor.
(B) Taxonomic cladogram from LEfSe, depicting taxonomic association from between microbiome communities from LTS and STS PDAC patients. Each node
represents a specific taxonomic type. Yellow nodes denote the taxonomic features that are not significantly differentiated between LTS and STS. Red nodes
denote the taxonomic types with more abundance in LTS than in STS, while the green nodes represent the taxonomic types more abundant in STS.
(C) LDA score computed from features differentially abundant between LTS and STS. The criteria for feature selection is log LDA score > 4.
(D) Heatmap of selected most differentially abundant features at the genus level. Highlighting three taxa enriched in LTS. The blue color represents less abundant,
lighter yellow color represents intermediate abundance and red represents the most abundant. Highlighting three taxa enriched in LTS.
(E) Kaplan-Meier estimates for survival probability based on the abundance levels of microbes enriched at Genus level in LTS. Right plot, Saccharopolyspora;
middle plot, Pseudoxanthomonas; and left plot, Streptomyces (p < 0.0001).
(F) Plots of differentially abundant genus significantly enriched in both MDA and JHH LTS patients. FDR adj p values from negative binomial test p value.
(G) ROC analysis of Taxa relative abundance as predictive of LTS status. The top 3 differential bacteria (genus) identified and Bacillus Clausii (one of top species)
were tested individually and in aggregate in the MDA discovery cohort (left panel) were then validated in the JHH validation cohort (right panel).
(H) Table depicting AUC of bacteria tested in (G) for both MDA and JHH cohorts.
See also Figures S2, S3, and S4 and Tables S1 and S2.
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Figure 3. Commensal Microbiome from LTS PDAC Patients Induces a Strong Immune Infiltration and Antitumoral Immune Response
(A) Immunohistochemical (IHC) staining of CD3, CD8, and granzyme B from tumors of STS and LTS PDAC patients (representative picture).
(B) Quantification of IHC of CD3, CD8, and granzyme B on STS and LTS PDAC patients.
(C) Representative pictures of multiplex immunofluorescence staining (multiplex IF) with Opal kit.
(D) Immunohistochemical staining of CD8 from tumors of STS and LTS PDAC patients from validation cohorts (JHH) (representative picture).
(E) Quantification of IHC of CD8 on STS and LTS PDAC patients from validation cohorts (JHH).
(F) Spearman correlation between CD3+, CD8+, and GzmB+ tissue densities and the overall survival (top) and alpha diversity by Shannon index (bottom) of all
PDAC patients.
(G) Spearman correlation between CD8+ tissue densities and Saccharopolyspora, Pseudoxanthomonas, and Streptomyces (p < 0.0001, p = 0.006, and
p < 0.0001, respectively) in PDAC patients.
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Figure 4. Gut Microbiota from PDAC Patients Can Influence Tumor Microbiota and Tumor Growth
(A) Taxonomic classification of bacterial 16S sequence detected in human samples by origin.
(B) Experimental design of fecal microbiota transplantation (FMT) from metastatic PDAC donors in C57BL/6 wild type mice treated with antibiotics (ATBx).
(C) Taxonomic classification of bacterial 16S sequence detected in human donor stools and FMT recipient mice (stools and tumors) by origin.
(D) PCA using unweighted UniFraC of beta diversity, showing closeness between mice that received FMT from PDAC STS patients and distance from those that
did not receive FMT.
(E) Experimental design of FMT from advanced PDAC (STS), PDAC LTS with no evidence of disease (LTS-NED), and healthy control (HC) donors in C57BL/6 wildtype mice treated with antibiotics (ATBx).
(F) Tumor volume from mice orthotopically implanted with KPC pancreatic cancer cell lines along with transplantation with stools from STS, LTS-NED, and HC
donors.
(G) Magnetic resonance imaging (MRI) scans of KPC-implanted mice transplanted with stools from STS, LTS-NED, and HC donors (representative images).

(legend continued on next page)
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actively modify the tumor microbiome by changing the gut microbiome, we performed fecal microbial transplantation (FMT)
from patients with advanced PDAC (STS) into mice previously
treated with antibiotics (ATBx). Human fecal material was transferred by oral gavage three times a week and weekly after
2 weeks. Mice were then challenged with orthotopic implantation of syngeneic cancer lines derived from genetically engineered Pdx1-Cre, LSL-KrasG12D/+, LSL-Trp53R172H/+ (KPC)
mice. We examined the OTUs abundance in the human STS
donor samples, murine fecal samples pre-FMT (basal condition),
post-FMT, and murine tumors at the end point of 5 weeks posttumor implantation. Interrogation of bacterial origin showed that
a large number of bacteria of human donor origin were found as
part of the murine gut microbiome (40%) of recipient mice
post-FMT (Figures 4B and 4C). Interestingly, we were able to
detect human donor bacteria in the murine tumor microbiome
post-FMT while it remained absent from mice who did not get
FMT (Figures 4B and 4C). However, the bacteria coming from
donors represented a small percent of the tumor microbiome
(< 5%), while the remaining 20% represented the basal murine
gut microbiome. Because over 70% of the tumor microbiome
was not representative of the gut microbiome (Figure 4C, gray
bars), we then wondered if FMT could modulate or shift the overall intratumoral bacterial composition, in addition to direct translocation. We used beta-diversity to generate a PCoA and a clear
differential clustering was detected between OTUs on tumors
from mice who received FMT versus mice that did not receive
FMT (p < 0.001) (Figure 4D). Additionally, we looked at the taxonomic composition of tumors and found significant changes in
individual bacterial populations after FMT (Figure S5A). Interestingly, one of the bacterial classes that increased in tumors from
mice who received FMT from STS donors was Clostridiales,
which was enriched in the original human STS tumor specimens.
This data suggests that the gut microbiome can modulate the tumor microbiome, in minor part by direct translocation into the tumors, but more significantly, by altering the microbial landscape.
In order to expand our findings to assess how tumor growth
may get affected by differential modulation of the tumor microbiome in response to recipient fecal transplants, we obtained
stool specimens from the following 3 groups of patients: PDAC
patients with advanced disease who would likely experience
STS, patients who had PDAC resected more than 5 years prior
to collection who would be classified as LTS with no evidence
of disease (LTS-NED), and healthy controls (HC). We employed
a similar FMT design as described above (Figure 4E). Five weeks
after tumor implantation we assessed gut and tumor microbiome
and tumor growth. Gut microbial beta-diversity distinguished the
three types of recipient mice (Figure S5B) and tumor microbial
beta-diversity differentially clustered mice groups according to
the type of FMT they received (Figures S5C–S5G).
We observed a significant reduction in tumor growth in mice
that received FMT from LTS-NED donors compared with the

mice transplanted with stools from STS donors (p < 0.001) or
HC donors (p = 0.02) (Figures 4F and 4G). These results suggest
that gut/tumor bacteria from patients who had PDAC and survived long-term may have a protective effect against tumors.
We also found that tumors from mice that got FMT from STS patients were larger than those from mice who got HC FMT, suggesting that PDAC-associated gut/tumor bacteria may exert a
tumor-promoting effect.
To confirm that the anti-tumoral effect exerted by LTS-NED
was definitively induced by change in bacterial content, we
treated mice transplanted with stools from LTS-NED with antibiotics post-FMT and compared with mice that did not receive antibiotics post-FMT (Figure S5H). We found that short-term antibiotics on mice that received FMT from LTS-NED donors induced
larger tumors than untreated mice by modifying the gut microbiome (Figures S5I and S5J). When we analyzed the tumor
microbiome of the two groups, we were indeed able to see differential clustering for beta-diversity between the two groups (Figure S5K). This data indicates that bacteria ablation can decrease
the anti-tumoral efficacy induced by LTS-NED FMT, which validates the central role of bacteria.
Next, we assessed whether the gut microbiome can influence
the pancreatic tumor immune infiltrates. Flow cytometry analysis
demonstrated that tumors from mice that received FMT from
LTS-NED had significantly higher numbers of CD8+ T cells, as
well as activated T cells (CD8+IFNg+ T cells) versus those with
stools transferred from STS or HC donors, whereas those who
received STS FMT had increased CD4+FOXP3+ and myeloidderived suppressor cells (MDSC) infiltration (Figure 4H). Additionally, mice receiving FMT from LTS-NED patients had higher
serum level of interferon-g (IFN-g) and interleukin-2 (IL-2)
(p < 0.05) compared with mice receiving STS FMT (Figure 4I).
To evaluate the role of T cells in mediating the observed phenotype, we depleted CD8+ T cells using neutralizing antibodies in
mice transplanted with LTS-NED stools and subsequently challenged with orthotopic tumors (Figure 4J). We found that CD8+
T cells depletion blocked the anti-tumoral effect induced by
LTS-NED FMT (Figure 4K), suggesting that the beneficial effect
of LTS-NED-associated gut/tumor bacteria is mediated by
CD8+ T cells. Together, these data strongly suggest that the
gut microbiome can colonize pancreatic tumors, modify its overall tumoral bacterial composition, and modulate immune function to ultimately affect the natural history and survival.
DISCUSSION
The microbiota can exert regulatory effects in other sites beyond
the gut. Our study represents the first report to explore the influence of the tumor microbiome on clinical outcomes. We have
performed a comprehensive analysis of the PDAC intratumoral
microbiome in two independent cohorts of LTS and STS survival
patients from different institutions. It is important to note that one

(H) Flow cytometry analysis of CD45+CD8+, CD45+CD8+IFN-g+, Treg (CD45+CD4+FOXP3+), and MDSC (CD45+CD11b+Ly-6G/Ly-6C+) cells from KPC-implanted
mice and transplanted with stools from STS, LTS-NED, and HC donors.
(I) Serum level of IL-2 and IFN-g in KPC-implanted mice and transplanted with stools from STS, LTS-NED, and HC donors.
(J) Experimental design of FMT from LTS-NED who received CD8 neutralizing antibodies versus isotype control.
(K) Tumor volume from KPC-implanted mice and transplanted with stools from LTS-NED who received CD8 neutralizing antibodies versus isotype control.
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of these cohorts (JHH) had already been examined for genomewide differences in the mutational landscape that could be
contributing to favorable survival and none were identified
(Dal Molin et al., 2015). Overall, we detected substantial abundance of microbiome in PDAC tumors from all patients, as previously reported (Geller et al., 2017). We found that PDAC patients
with the uncommon phenotype of LTS had significantly higher
tumor bacteria diversity that the patients with more typical
shorter survival. Further, the LTS and STS cohorts each had a
distinctive tumor microbiome signature with specific bacterial
genus that was predictive of survival in a multi-variate analysis.
Notably, we demonstrated for the first time that the microbiota
reconstitution by FMT with stool from HC, STS, or LTS-NED patients in tumor-bearing mice mirrors the recruitment, or lack
thereof, of immune cells to the tumor milieu seen in the respective cohorts and influences tumor growth, supporting a causal
role for the gut microbiome in shaping tumor immune responses
and PDAC progression.
Recent studies have shown that the gut microbiome composition can improve the outcome of cancer immunotherapy
(anti-CTLA4 and anti-PD-L1) by influencing the immune system
(Gopalakrishnan et al., 2018; Matson et al., 2018; Routy et al.,
2018). Our finding suggests that, independent of therapy, the
PDAC tumor microbiome diversity and composition can influence immune infiltration that ultimately influences PDAC survival. Importantly, we found a signature of 3 tumor bacterial
taxa: Sachharopolyspora, Pseudoxanthomonas, and Streptomyces significantly enriched in LTS patients. Presence of
Bacillus clausii, one of the top species enriched in LTS, combined with the three genus signature, was highly predictive of
long-term survivorship in the MDA discovery cohort and validated in the JHH cohort. In the future, tumor microbiome
sequencing could be used to stratify patients for adjuvant trials,
including microbiome interventions.
Although the greater microbial diversity could have an immunoregulatory impact, its role in the antitumor response is
not entirely clear. Components of the Saccharopolyspora
family, specifically Saccharopolyspora rectivirgula, have been
described as having a role in inflammatory lung diseases, such
as hypersensitivity pneumonitis that are associated with IFN-g
overproduction (Kim et al., 2010). The presence of Saccharopolyspora spp could contribute toward generating a pro-inflammatory microenvironment mediated by cytokines and chemokines
that recruit inflammatory cells and IFN-g secretion. However,
its role in PDAC remains to be explored. Future investigations
will determine if similar mechanism can be used by the tumor microbiota to modulate the immune system by improving or impairing the immune response against the tumor.
Most of the bacterial communities found in the tumoral milieu
are present commonly in the gut microbiome (Human Microbiome Project Consortium, 2012b; Lloyd-Price et al., 2017),
suggesting that potentially bacterial translocation from the gut
to the pancreas might be occurring. We demonstrate for the
first time in human PDAC patients that the gut microbiota has
the capacity to colonize pancreatic tumors and that this colonization can modify the overall microbiome of the tumor. Additionally, our preclinical data shows that the modification of
the gut/tumor microbiome with human flora from LTS-NED pa-
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tients is able to induce an antitumor response and activation of
the immune system in tumor-bearing mice, which is not
observed in FMT from STS PDAC patients. Furthermore, we
have found that immunosuppressive populations were also
modulated with stools from survivors or healthy patients by
decreasing tumor infiltration by Tregs. This could be a potential
mechanism for certain bacteria to promote immune activation.
Microbiome-dependent CD8 T cell activation may play a key
role. Further studies are needed with in human PDAC patients
to determine how FMT can induce changes in the microbiome
tumor and immune activation. Additionally, the potential evaluation of cross-reactivity between T cells that recognize tumor
neoantigens and microbial antigen (mimicry) present in the tumor should be conducted in future studies as they may be useful in understanding mechanisms by which bacteria can exert
immuno-activating effects but also may be useful in the design
on novel therapeutic strategies.
In conclusion, we found that the tumor microbiome diversity
has a powerful effect in determining the survival of PDAC
patients. The tumor microbiome unique to LTS may contribute
toward shaping a favorable tumor microenvironment, characterized by the recruitment and activation of CD8 T cells to the
tumor milieu, and it might also be useful as a predictor of patients’ outcomes. Besides the microbiome-based prognostic
tool, the results of FMT represent an immense therapeutic
opportunity to manipulate the microbiome to improve the life
expectancy of PDAC patients in whom few therapeutic options
exist.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Tumor Specimens
We initially used a discovery cohort of patients with long-term survivors PDAC (> 5-years overall survival, median survival 10.14 years,
called LTS, n = 22), compared with stage-matched PDAC patients who survive less than 5 years (median survival 1.62 years, called
STS, n = 21) from the University of Texas MD Anderson Cancer Center (MDACC), Houston, TX. Detailed clinical and pathologic information on the patients are presented in Table 1. A second validation cohort with very long-term survivors of similar characteristics
of survival (> 10 years overall survival, n = 15) were compared with stage-matched regular PDAC patients who survive less than
5 years (n = 10), from Johns Hopkins Hospital (JHH), Baltimore, MD. Archived formalin-fixed paraffin-embedded (FFPE) tumor specimens obtained from these patients who underwent surgical resection with curative intent were collected from MDACC and JHH. The
staging of disease was reviewed and updated to comply with the 7th Edition of the American Joint Committee on Cancer classification. The study protocols were approved by the Institutional Review Board at MDACC and JHH.
Human Stool Samples
Stool collection from PDAC STS, PDAC LTS-NED patients and healthy control (HC) donors were collected on OMNIgene GUT kit.
Fresh stools for fecal microbiota transplantation (FMT) studies were collected and frozen at 80 C prior to FMT.
Murine studies
Antibiotic treatments and Fecal microbiota transplantation (FMT)
All animal experiments were carried out in compliance and approved by the Animal Care and Use Committee at The UT MD Anderson
Cancer Center. Female C57BL/6 aged 6 weeks were purchased from Taconic Biosciences, USA. Mice were treated for two weeks
with an antibiotic solution (ATBx) containing streptomycin (5 mg/ml), and clindamycin (0.1 mg/ml) added to the sterile drinking water
of mice ad libitum. Solutions and bottles were changed 2 times a week. After two weeks, ATBx treatment was stopped and the mice
were recolonized by FMT, receiving stool from patients with PDAC STS, LTS-NED or HC donors. Mice received stools a total of 3
times/ week by oral gavage using animal feeding needles before undergoing orthotopic tumor implantation and once/week after
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the tumor implantation until the end point. For CD8+ T cells depletion experiments, mice were treated for two weeks, biweekly with
150ug of antibodies against mouse CD8a (by intraperitoneal injections). For late bacterial ablation experiments, mice transplanted
with stools from LTS-NED were treated with antibiotics post-FMT in the last two weeks of the experiment.
Orthotopic tumor implantation
C57BL/6 mice were anesthetized with 2% isoflurane in oxygen. A lateral incision was made on the abdominal wall of each mouse and
tumors were implanted orthotopically in the pancreas with 2 3 104 KPC pancreatic adenocarcinoma cell lines. Tumor growth was
monitored by Magnetic Resonance Imaging (MRI) of mice body at 4 weeks after the tumor implantation. At the endpoint, tumors,
fecal and blood specimens were harvested and processed for further analysis.
METHOD DETAIL
DNA extraction and bacterial 16S rRNA sequencing
16S rRNA gene sequencing methods were adapted from the methods developed for the Earth Microbiome Project (X) and NIH-Human Microbiome Project (Human Microbiome Project Consortium, 2012a, 2012b; Caporaso et al., 2012). Briefly, three sections of 10
um of FFPE of PDAC tissue were aseptically collected and placed in 1.5ml Eppendorf tube. Normal pancreatic tissue and paraffin
without tissue were used as controls. Bacterial genomic DNA was extracted using QIAGEN QIAamp DNA FFPE. The 16S rDNA
V4 region was amplified by PCR and sequenced in the MiSeq platform (Illumina) using the 2x250 bp paired-end protocol yielding
pair-end reads that overlap almost completely. The primers used for amplification contain adapters for MiSeq sequencing and single-index barcodes so that the PCR products may be pooled and sequenced directly (Caporaso et al., 2012), targeting at least 10,000
reads per sample. 16S (variable region 4 [v4]) rRNA gene pipeline data incorporated phylogenetic and alignment based approaches
to maximize data resolution. The read pairs were demultiplexed based on unique molecular barcodes added via PCR during library
generation, then merged using USEARCH v7.0.1090 (Edgar, 2010).
Microbiome Pipeline Analysis steps
 and Salzberg, 2011) and subRaw paired-end 16S rRNA reads (V4 region) were merged into consensus fragments by FLASH (Magoc
sequently filtered for quality (targeted error rate < 0.5%) and length (minimum 200bp) using Trimmomatic (Bolger et al., 2014) and
QIIME (Caporaso et al., 2010a; Kuczynski et al., 2011). Spurious hits to the PhiX control genome were identified using BLASTN
and removed. Passing sequences were trimmed of primers, evaluated for chimeras with UCLUST (de novo mode) (Edgar et al.,
2011), and screened for human-associated contaminants using Bowtie2 (Langmead and Salzberg, 2012). Chloroplast and mitochondrial contaminants were detected and filtered using the RDP classifier (Wang et al., 2007) with a confidence threshold of 50%. Highquality passing 16S rRNA sequences were assigned to a high-resolution taxonomic lineage using Resphera Insight (Daquigan et al.,
2017; Drewes et al., 2017) and SILVA Database v128 (Quast et al., 2013). Bacterial contaminant removal was performed using four
paraffin-only samples (no tissue) and additional literature. Contaminant list can be found in Table S2C. Resulting contaminant-free
16S rRNA profiles were subsampled to 2,000 sequences per sample for downstream comparative analysis. Alpha- and beta-diversity
analysis and principal coordinates analysis utilized QIIME and R. Differential abundance analysis of alpha diversity features of interest
evaluated differences using the nonparametric difference test. Differential abundance analysis of taxonomic abundances evaluated
differences using the negative binomial test (DESeq) (Anders and Huber, 2010). The false discovery rate (FDR) was used to correct for
multiple hypothesis testing (Benjamini et al., 2001). Generalized linear modeling adjusting for cohort membership and survival status
was performed using R. LEfSe was used for linear discriminant analysis (Segata et al., 2011). High-quality non-contaminant 16S rRNA
sequences were analyzed for functional gene content using PICRUSt (Langille et al., 2013) which provides proportional contributions
of KEGG categories for each sample (Kanehisa and Goto, 2000). Differentially abundant functional categories (KEGG Level 2, FDR
adj.p < 0.05 MDA cohort) were utilized for visualization as a heatmap. Relative abundance values were mean centered by functional
 and Salzberg, 2011). Statistical
category and colored according to enrichment or depletion between LTS and STS groups (Magoc
annotations are added to denote significant correlations with metadata, enabling quick assessment of many variables. Receiver
Operator Characteristic (ROC) and Area Under Curve (AUC) analysis were performed using R, evaluating variable thresholds for relative abundance of taxa individually and in aggregate for classification of LTS versus STS status. Sensitivity was calculated as
100*(number of true positive LTS / total LTS). Specificity was calculated as 100*(number of true negative STS / total STS).
Chromogenic Immunohistochemistry (IHC)
4 mm sections of FFPE tumor tissue were mounted on Superfrost Plus Microscope Slides (FisherScientific) and prepared for IHC and
Multiplex IF. The slides were deparaffinized in xylene and rehydrated in graded ethanol. Antigen retrieval was performed in citrate
buffer (citrate pH 6.0) using microwave heating (EZ Retriever by BioGenex). Chromogen-based IHC analysis was performed by using
anti-human antibodies against the following: CD3 (T cell lymphocytes), CD8 (CD8 T cells), Granzyme B (GzmB), FOXP3 (regulatory
T cell), CD68 (Macrophages), CD66b (Granulocytes/MDSC). Signal Stain DAB Substrate KIT (Cell signal, Danvers, MA) was used for
IHC detection and hematoxylin counterstaining. The densities of cells expressing CD3, CD8 and GzmB were measured by quantifying positively stained cells in five random square areas (1 mm2 each) in the tumor. The average total number of cells positive for
each marker in the five square areas was expressed in density per mm2.
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Multiplex Immunofluorescence Staining (Multiplex IF)
Staining was performed manually using the same primary antibodies used for IHC analysis against markers: Cytokeratin AE1/AE3
(Epithelial cell marker), Smooth Muscle Actin (Alpha-smooth muscle isoform of actin), CD3, CD8, Granzyme B and FOXP3. Antibody
detection was performed with Opal Polymer HRP Ms + Rb immunohistochemistry detection reagent (PelkinElmer, Boston, MA).
Staining was performed consecutively by using the same protocol as described for IHC, and the detection for each marker was
completed before application of the next antibody. The Opal Polymer HRP Ms + Rb detection reagent was used for the primary antibody detection and Opal 7-Color Manual IHC, with 6 reactive fluorophores Opal 520, Opal 540, Opal 570, Opal 620, Opal 650, Opal
and 690 plus 40 ,6-diamidino-2-phenylindole (DAPI) nuclear counterstain, were added according to the manufacturer’s instructions.
Uniplex IF and Negative controls were stained with the same protocols. At the conclusion of the staining, slides were imaged using
Vectra 3.0 spectral imaging system (PerkinElmer) according to previously published instructions.
Lipopolysaccharide (LPS) staining and Ribosomal RNA (rRNA) Fluorescence In Situ Hybridization (FISH)
Slides were stained for bacteria with the automated slide stainer BOND RXm (Leica) using the Bond polymer refine detection kit, according to manufacturer’s instructions. Heat induced epitope retrieval (HIER) at pH6 was done by a 20 min heating step with the
epitope retrieval solution 1 (BOND). Gram negative were stained with Lipopolysaccharide Core (1:1000 dilution).
FISH was executed using Vysis IntelliFISH Universal FFPE Tissue Pretreatment and Wash Reagents Kit (Abbott Molecular Inc, IL).
5 mm sections of FFPE tumor tissue were hybridized to a probe that recognizes the 16S rRNA genes of all bacteria (green) (Salzman
et al., 2010) and counterstained with DAPI to visualize nuclei (blue), and tissues were visualized using a Nikon Eclipse Ti microscope.
Flow Cytometry
To characterize different subpopulations of immune cells, murine orthotopic PDAC tumors were removed and single cell suspensions
were obtained by digestion with Collagenase P. Cells were stained with anti-Mouse antibodies against: CD45, CD4, FoxP3, Ly-6G,
Ly-6C, IFN-g and CD8a. Sample acquisition was carried out on LSRFortessa X-20 Analyzer Flow Cytometer (BD Biosciences,
Franklin Lakes, NJ). Analysis was performed with FlowJo version 10.
Tissue culture based and 16S rDNA PCR
Frozen PDAC tissue samples were gently digested with collagenase P in sterile conditions to obtain a single cell suspension. Once
the cell fraction was obtained, it was pelleted and the supernatants were plated on Columbia agar and maintained under aerobic and
anaerobic conditions overnight at 37 C. Bacterial colonies were selected and DNA was extracted for subsequent PCR amplification
of the 16S rDNA using the primers 515F–806R targeting the V4 region of the 16S rRNA.
For 16S rDNA PCR, bacterial DNA was extracted from frozen PDAC tissue samples maintaining sterile conditions using DNA
QIAamp DNA Mini Kit (QIAGEN). 16S rDNA PCR was executed using the primers 515F–806R targeting the V4 region of the 16S rRNA.
QUANTIFICATION AND STATISTICAL ANALYSES
The patients’ demographic and clinical information were compared using chi-square test and Fisher’s exact test were used to evaluate the association between two categorical variables. Wilcoxon’s rank sum test was used to compare the distributions of continuous variables between two different groups (microbiota composition positive versus negative). Overall survival (OS) was defined as
the time from diagnosis to death from any cause. Patients who did not experience death were censored at date of last follow-up.
Kaplan-Meier curves were estimated for the survival distributions. The Log-rank test was used to test the difference in survival distributions between subgroups. Univariate Cox proportional hazard models were used to determine the effects of microbiota composition on OS (Heller, 2001). Hazard ratios and 95% confidence intervals were provided. All tests were two-sided. P values less than
0.05 were considered statistically significant. All analyses were conducted using SAS 9.4 and S-Plus 8.0 software. Raw 16S rRNA
sequences were processed using QIIME (Caporaso et al., 2010b). The minimal sequencing depth was 817, mean: 22178 and
maximal: 89566. Sequences were aligned with reference to Silva v128 (Quast et al., 2013). Alpha- and beta-diversity analysis, survival
analysis, principal coordinates analysis, ecological network analysis and Logistic regression combined with LASSO method utilized R
3.4.3. For LASSO logistic regression, we ran 10-fold cross validations with logistic regression for 100 times (starting with different
seeds), then we aggregated all the deviances from 100 validation results with respect to each tuning parameter of lambda. The
one with minimal average deviance was set as the best lambda value. Then we fit the LASSO logistic regression again with this
best lambda value to get a stable set of selected features. Linear discriminant analysis (LDA) effect size (LEfSe) was performed under
bioconda environment (Segata et al., 2011) to determine the genomic features most likely to explain differences between biological
classes (STS and LTS of MDACC cohorts). All p values were adjusted for multiple comparisons with the FDR algorithm (Benjamini
et al., 2001). For the discovery, validation and prioritization of candidate taxa, the procedure was the following; all genera/species
from the discovery cohort (MDACC) with an FDR adjusted p value < 0.05 between LTS and STS were included. Those genera/species
that remained significantly associated with LTS and STS in the validation cohort (JHH) were selected as candidates. Finally, the prioritization of the final candidates list required the candidate genera/species remain significantly associated with LTS/STS status
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(p < 0.01) independent of cohort using a generalized linear model. IHC, Flow cytometry, Mouse Chemokine Assays and tumor size
data were analyzed and expressed as the mean ± standard deviation using GraphPad Prism 7 (GraphPad Software, Inc.,
San Diego, CA).
DATA AND CODE AVAILABLE
The raw data is deposited and available on NCBI BioProject Accession Number: PRJNA542615. All analyses were conducted using
SAS 9.4 and S-Plus 8.0 software. Raw 16S rRNA sequences were processed using QIIME (Caporaso et al., 2010b). Logistic regression combined with LASSO method utilized R 3.4.3. Linear discriminant analysis (LDA) effect size (LEfSe) was performed under
bioconda environment (Segata et al., 2011). All p values are adjusted for multiple comparisons with the FDR algorithm
(Benjamini et al., 2001).
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Supplemental Figures

Figure S1. Analysis of Alpha-Diversity Based on Influencing Factors in MDACC Cohort, Related to Figure 1
(A–F) Alpha diversity boxplots (Observed species and Shannon) in MDACC cohorts PDAC patients. Analysis of following factors: body mass index (BMI) (A), sex
(B), Smoking status (C), neoadjuvant therapies (D), adjuvants therapies (E) and antibiotics (F).

Figure S2. Taxonomic Composition Based on Influencing Factors, Related to Figure 2
(A–E) Bar plots displaying taxonomic composition in both cohorts at phylum level (A), class level (B), order level (C), family level (D), and genus level (E). Relative
abundance is plotted for each tumor (0%–100%).
(F–H) Bar plots comparing taxonomic composition (order level) in MDACC cohort based on following potentially influential factors: Neoadjuvant therapies (F),
Adjuvants therapies (G) and Antibiotics usage prior to surgery (+3 days) (H).

Figure S3. Validation Methodologies for Bacteria Detection in PDAC Tissue Related to Figure 2
In (A) is the fluorescence in situ hybridization (FISH) in human FFPE PDAC samples to detect bacterial 16S rRNA sequences (green). Cell nuclei
stained with 40 ,6-diamidino-2-phenylindole (DAPI). (B) Lipopolysaccharide (LPS) staining in FFPE PDAC samples by immunohistochemistry using an

(legend continued on next page)

antibacterial-LPS antibody. (C) 16S rDNA PCR executed using the primers 515F–806R target the V4 region of the 16S rRNA, shows the presence of
bacterial DNA in 9 PDAC frozen samples. (D) PCR of Saccharopolyspora rectivirgula on PDAC LTS frozen samples. (E) Bar plots of taxonomic
composition from FFPE and frozen PDAC samples at Genus level. (F) Culture based assay from frozen PDAC samples. (G) 16S rDNA PCR from colonies
selected on agar plate.

Figure S4. Microbiome Communities from LTS and STS Drive Different Metabolic Pathways, Related to Figure 2
In (A) is a heatmap of PICRUSt analysis identifing 26 core functional modules present across all PDAC samples with a coverage of > 90% and p < 0.05. (B) LDA
score computed from enrichment metabolic pathways between LTS and STS. (C) Kaplan-Meier estimates for survival probability based on the top two enrich
metabolic pathways in LTS. Upper plot, Xenobiotics Biodegradation and Metabolism (p < 0.00001) and lower plot, Lipids Metabolism (p < 0.00001).

(legend on next page)

Figure S5. Tumor Microbiome Changes Driven by FMT and Role of Antibiotics in Attenuating the Anti-tumoral Effect Induced by LTS-NED
FMT, Related to Figure 4
In (A) are stacked bar plots showing taxonomic composition (Order level) on tumors from mice who did not receive FMT (no FMT) versus those who received
PDAC FMT. (B) Beta diversity through LDA comparing gut microbiome from: HC, LTS-NED and STS. (C-G) Beta-diversity through PCA/Soransen methods
comparing tumor microbiome from the different groups. (H) Experimental design of the bacterial ablation by antibiotics after FMT. (I) Tumor volume from mice
orthotopically implanted with KPC pancreatic cancer cell lines and FMT with stool from LTS-NED donors and antibiotic treated after FMT.(J) Taxonomic classification of bacterial 16S sequence detected in stools from human LTS donors and FMT recipient mice (pre/post antibiotics) by origin. (K) Beta diversity by PCA,
showing closeness between mice that received FMT from LTS-NED and distance from those that received FMT and were treated with antibiotics post-FMT.

